Europe – EU awards Active Implants a grant of around $6.8M

The grant is for the development of a meniscus implant adapted to the patient and capable of releasing drugs.

Israeli-US company Active Implants has won a grant under the European Union’s Horizon 2020 program. The grant is for the development of a future meniscus implant adapted to the patient and capable of releasing various drugs within the knee cavity after being implanted.

The €6 million grant was awarded jointly to a group of research centers, clinical centers and commercial companies in Europe. Active Implant’s share is €1 million, and it is leading development of the future synthetic implant. The product will be based on the company’s existing technology, an implant that serves as a shock absorber in the event of injury to the meniscus.

Sales of the existing product will start in Europe in July, and the company estimates that it will receive US Food and Drug Administration approval for it by the end of 2020. The product has undergone clinical trials on about 350 patients. The difference between the two products is that the new implant under development will be adapted to each individual patient and will also release drugs that encourage healing of the meniscus…